Knowledge about breast cancer risk factors and hereditary breast cancer among early-onset breast cancer survivors

Familial Cancer

Volumn 1, Issue 3-4, 2001, Pages 135-141

  Miesfeldt, Susan ^a   Cohn, Wendy ^a   Ropka, Mary ^a   Jones, Susan ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Education; Genetic counseling; Hereditary breast cancer; Information needs; Knowledge; Risk

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; FAMILIAL CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; RISK FACTOR;

AGE OF ONSET; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MIDDLE AGED; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SURVIVORS;

CARTHAMUS; CARTHAMUS TINCTORIUS;

EID: 0035782961     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021189128084     Document Type: Article

References (31)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. Can Cancer J Clin 2002; 52: 23-47.
2. Claus EB, Schildkaraut JM, Thompson WD et al. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77: 2318-24.
3. Eng C, Hampel H, de la Chapelle A. Genetic testing for cancer predisposition. Annu Rev Med 2000; 52: 371-400.
4. Ang P, Garber JE. Genetic susceptibility for breast cancer - Risk assessment and counseling. Semin Oncol 2001; 28: 419-33.
5. Verhoog LC, Brekelmans CTM, Seynaeve C et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351: 316-21.
6. Ford D, Easton DF, Bishop DT et al. Risks of cancer in BRCA1-mutation carriers. Lancet 1994; 343: 692-5.
7. Verhoog LC, Brekelmans CTM, Seynaeve C et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 1999; 17: 3396-402.
8. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 15: 1310-6.
9. Easton DF, Bishop DT, Ford D et al. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995; 56: 267-71.
10. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCAI and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-8.
11. Thompson D, Easton D, on behalf of the Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001; 68: 410-9.
12. Lerman C, Biesecker B, Benkendorf JL et al. Controlled trial of pretest education approaches to enhance informed decision-making for BRCAI testing. J Natl Cancer Inst 1997; 89: 148-57.
13. Mouchawar J, Byers T, Cutter G et al. A study of the relationship between family history of breast cancer and knowledge of breast cancer genetic testing prerequisites. Cancer Detect Prev 1999; 23: 22-30.
14. Ludman EJ, Curry SJ, Hoffman E et al. Women's knowledge and attitudes about genetic testing for breast cancer susceptibility. Eff Clin Pract 1999: 2; 158-62.
15. Hughes C, Gomez-Caminero A. Benkendorf J et al. Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Patient Educ Couns 1997; 32: 51-62.
16. Donovan KA, Tucker DC. Knowledge about genetic risk for breast cancer and perceptions of genetic testing in a sociodemographically diverse sample. J Behav Med 2000; 23: 15-36.
17. Bluman LG, Rimer BK, Berry DA et al. Attitudes, Knowledge and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol 1999; 17: 1040-6.
18. Randall J, Butwo P, Kirk J et al. Psychological impact of genetic counselling and testing in women previously diagnosed with breast cancer. Int Med J 2001; 31: 397-405.
19. Dillman DA. Mail and Telephone Surveys: The Total Design Method. New York: John Wiley and Sons, 1978.
20. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCAI and BRCA2. JAMA 1997; 277: 997-1003.
21. Hartmann LC, Schaid DJ, Woods JE et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77-84.
22. Meijers-Heijboer H, van Geel B, van Putten WLJ et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-64.
23. Hartmann LC, Sellers TA, Schaid DJ et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633-7.
24. Rebbeck TR, Levin AM, Eisen A et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91: 1475-9.
25. Eisen A, Rebbeck TR, Wood W, Weber B. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 2000; 18: 1980-95.
26. Narod SA, Brunet JS, Ghadirian P et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet 2000; 356: 1876-81.
27. King MC, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA 2001; 286: 2251-5.
28. Lerman C, Narod S, Schulman K et al. BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes. JAMA 1996; 275: 1885-92.
29. Luker KA, Leinster S, Owens G et al. Preferences for Information and Decision Making in Women with Newly Diagnosed Breast Cancer. Final Report. London: Cancer Macmillan Fund, 1993.
30. Degner L. Boman D. Kristjanson L et al. Profiles of Information Needs in Women with Breast Cancer: Cross Cultural Comparisons. Research Report. Winnipeg: University of Manitoba, 1994.
31. Chalmers K, Thomson K, Degner L. Information, support and communication needs of women with a family history of breast cancer. Cancer Nuts 1996; 19: 204-13.